Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine.
“We are pleased that this new data shows antibody persistence through six months following the second dose of our Covid-19 vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This gives us further confidence in the protection afforded by our Covid -19 vaccine. We remain committed to continuing to address the Covid -19 pandemic.”
This study analysed 33 healthy adult participants in the NIH-led Phase I study of Moderna’s Covid-19 vaccine at six months following the second 100 μg dose (day 209). As detected by three distinct serologic assays, antibodies elicited by the Moderna Covid-19 vaccine persisted through six months after the second dose. Antibody decay was estimated using two approaches and was consistent with published observations of convalescent patients with Covid-19 through eight months after symptom onset.
Studies monitoring immune responses beyond six months are ongoing. Out of caution, Moderna is also pursuing a clinical development strategy against emerging variants. Additionally, NIAID, part of the National Institutes of Health (NIH), will conduct a Phase I clinical trial to assess the monovalent and multivalent modified mRNA-1273 vaccines as a primary series in naïve individuals and as a booster vaccine in those previously vaccine with mRNA-1273.